BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ueda M, Toji E, Nunobiki O, Izuma S, Okamoto Y, Torii K, Noda S. Germline polymorphism of cancer susceptibility genes in gynecologic cancer. Hum Cell 2008;21:95-104. [PMID: 19067761 DOI: 10.1111/j.1749-0774.2008.00058.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Nunobiki O, Sano D, Hata S, Ogasawara T, Ueda M. Clinical significance of hWAPL polymorphisms in the risk of cervical carcinogenesis. Hum Cell 2018;31:149-53. [PMID: 29362984 DOI: 10.1007/s13577-018-0200-7] [Reference Citation Analysis]
2 Yi K, Yang L, Lan Z, Xi M. The Association Between p53 Codon 72 Polymorphism and Endometrial Cancer Risk: A System Review and Meta-analysis. Int J Gynecol Cancer 2016;26:1121-8. [DOI: 10.1097/igc.0000000000000725] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Sanjari Moghaddam A, Nazarzadeh M, Noroozi R, Darvish H, Mosavi Jarrahi A. XRCC1 and OGG1 Gene Polymorphisms and Breast Cancer: A Systematic Review of Literature. Iran J Cancer Prev 2016;9:e3467. [PMID: 27366307 DOI: 10.17795/ijcp-3467] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
4 Dholariya S, Mir R, Zuberi M, Yadav P, Gandhi G, Khurana N, Saxena A, Ray PC. Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients. Clin Transl Oncol 2016;18:73-81. [PMID: 26209050 DOI: 10.1007/s12094-015-1338-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
5 Nunobiki O, Ueda M, Akise H, Izuma S, Torii K, Okamoto Y, Tanaka I, Noda S, Akashi K, Higashida T. GSTM1, GSTT1, and NQO1 polymorphisms in cervical carcinogenesis. Hum Cell 2015;28:109-13. [PMID: 25697264 DOI: 10.1007/s13577-015-0111-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
6 Nunobiki O, Sawada H, Ueda M. MDM2 SNP309 (rs2279744) and p53 Codon Arg72Pro (rs1042522) SNP in Cervical Carcinogenesis. ABB 2014;05:617-622. [DOI: 10.4236/abb.2014.57072] [Reference Citation Analysis]
7 Zhen S, Hu CM, Bian LH. Glutathione S-transferase polymorphism interactions with smoking status and HPV infection in cervical cancer risk: an evidence-based meta-analysis. PLoS One 2013;8:e83497. [PMID: 24391774 DOI: 10.1371/journal.pone.0083497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
8 Zhang Y, Tong S, Guan L, Na F, Zhao W, Wei L. CD95 rs1800682 polymorphism and cervical cancer risk: evidence from a meta-analysis. Tumour Biol 2014;35:1785-90. [PMID: 24114012 DOI: 10.1007/s13277-013-1237-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
9 Shen J, Sun NX. Association between FAS A670G polymorphism and susceptibility to cervical cancer: evidence from a meta-analysis. Tumour Biol 2013;34:3443-8. [PMID: 23900676 DOI: 10.1007/s13277-013-0920-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
10 Gao LB, Pan XM, Li LJ, Liang WB, Bai P, Rao L, Su XW, Wang T, Zhou B, Wei YG, Zhang L. Null genotypes of GSTM1 and GSTT1 contribute to risk of cervical neoplasia: an evidence-based meta-analysis. PLoS One 2011;6:e20157. [PMID: 21629772 DOI: 10.1371/journal.pone.0020157] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
11 Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, Okamoto Y, Torii K, Noda S. MDM2 SNP 309 human papillomavirus infection in cervical carcinogenesis. Gynecologic Oncology 2010;118:258-61. [DOI: 10.1016/j.ygyno.2010.05.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
12 Conesa-zamora P, Santaclara V, Gadea-niñoles E, Ortiz-reina S, Perez-guillermo M. Association of polymorphism in FcGR3A gene and progression of low-grade precursor lesions of cervical carcinoma. Human Immunology 2010;71:314-7. [DOI: 10.1016/j.humimm.2009.11.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
13 Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, Okamoto Y, Torii K, Noda S. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Human Cell 2009;22:101-6. [DOI: 10.1111/j.1749-0774.2009.00075.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
14 Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, Okamoto Y, Torii K, Noda S. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell 2009;22:49-54. [PMID: 19379464 DOI: 10.1111/j.1749-0774.2009.00068.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
15 Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U, Scott RJ. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol 2009;113:109-14. [PMID: 19193430 DOI: 10.1016/j.ygyno.2008.12.036] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]